Abbvie Inc Stock Beta
| ABBV Stock | USD 164.66 0.41 0.25% |
AbbVie Inc fundamentals help investors to digest information that contributes to AbbVie's financial success or failures. It also enables traders to predict the movement of AbbVie Stock. The fundamental analysis module provides a way to measure AbbVie's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AbbVie stock.
AbbVie | Beta |
AbbVie Inc Company Beta Analysis
AbbVie's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current AbbVie Beta | 0.56 |
Most of AbbVie's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AbbVie Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
AbbVie Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for AbbVie is extremely important. It helps to project a fair market value of AbbVie Stock properly, considering its historical fundamentals such as Beta. Since AbbVie's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of AbbVie's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of AbbVie's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, AbbVie Inc has a Beta of 0.564. This is 34.42% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
AbbVie Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AbbVie's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AbbVie could also be used in its relative valuation, which is a method of valuing AbbVie by comparing valuation metrics of similar companies.AbbVie is currently under evaluation in beta category among related companies.
AbbVie ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, AbbVie's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to AbbVie's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
AbbVie Institutional Holders
Institutional Holdings refers to the ownership stake in AbbVie that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of AbbVie's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing AbbVie's value.| Shares | Northern Trust Corp | 2023-12-31 | 20.9 M | Norges Bank | 2023-12-31 | 20.8 M | Bank Of America Corp | 2023-12-31 | 18.6 M | Legal & General Group Plc | 2023-12-31 | 15.2 M | Ameriprise Financial Inc | 2023-12-31 | 14.2 M | Fmr Inc | 2023-12-31 | 11.1 M | Ubs Group Ag | 2023-12-31 | 10.9 M | Hhg Plc | 2023-12-31 | 9.7 M | T. Rowe Price Associates, Inc. | 2023-12-31 | 9.5 M | Vanguard Group Inc | 2023-12-31 | 160.4 M | Blackrock Inc | 2023-12-31 | 143.2 M |
As returns on the market increase, AbbVie's returns are expected to increase less than the market. However, during the bear market, the loss of holding AbbVie is expected to be smaller as well.
AbbVie Fundamentals
| Return On Equity | 0.35 | ||||
| Return On Asset | 0.0807 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.32 % | ||||
| Current Valuation | 334.92 B | ||||
| Shares Outstanding | 1.77 B | ||||
| Shares Owned By Insiders | 0.10 % | ||||
| Shares Owned By Institutions | 71.90 % | ||||
| Number Of Shares Shorted | 13.12 M | ||||
| Price To Earning | 21.28 X | ||||
| Price To Book | 27.74 X | ||||
| Price To Sales | 5.29 X | ||||
| Revenue | 54.32 B | ||||
| Gross Profit | 41.53 B | ||||
| EBITDA | 18.1 B | ||||
| Net Income | 4.88 B | ||||
| Cash And Equivalents | 11.88 B | ||||
| Cash Per Share | 6.72 X | ||||
| Total Debt | 59.38 B | ||||
| Debt To Equity | 4.37 % | ||||
| Current Ratio | 0.93 X | ||||
| Book Value Per Share | 5.87 X | ||||
| Cash Flow From Operations | 22.84 B | ||||
| Short Ratio | 2.04 X | ||||
| Earnings Per Share | 2.71 X | ||||
| Price To Earnings To Growth | 0.45 X | ||||
| Target Price | 184.49 | ||||
| Number Of Employees | 50 K | ||||
| Beta | 0.56 | ||||
| Market Capitalization | 287.8 B | ||||
| Total Asset | 134.71 B | ||||
| Retained Earnings | (1000 M) | ||||
| Working Capital | (4.84 B) | ||||
| Current Asset | 16.31 B | ||||
| Current Liabilities | 10.89 B | ||||
| Annual Yield | 0.04 % | ||||
| Five Year Return | 4.33 % | ||||
| Net Asset | 134.71 B | ||||
| Last Dividend Paid | 5.99 |
About AbbVie Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AbbVie Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AbbVie using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AbbVie Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with AbbVie
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AbbVie position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AbbVie will appreciate offsetting losses from the drop in the long position's value.Moving together with AbbVie Stock
| 0.85 | EOLS | Evolus Inc Financial Report 14th of May 2024 | PairCorr |
Moving against AbbVie Stock
| 0.45 | LPTX | Leap Therapeutics Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to AbbVie could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AbbVie when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AbbVie - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AbbVie Inc to buy it.
The correlation of AbbVie is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AbbVie moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AbbVie Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AbbVie can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out AbbVie Piotroski F Score and AbbVie Altman Z Score analysis. Note that the AbbVie Inc information on this page should be used as a complementary analysis to other AbbVie's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for AbbVie Stock analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is AbbVie's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AbbVie. If investors know AbbVie will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AbbVie listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.67) | Dividend Share 5.99 | Earnings Share 2.71 | Revenue Per Share 30.723 | Quarterly Revenue Growth (0.05) |
The market value of AbbVie Inc is measured differently than its book value, which is the value of AbbVie that is recorded on the company's balance sheet. Investors also form their own opinion of AbbVie's value that differs from its market value or its book value, called intrinsic value, which is AbbVie's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AbbVie's market value can be influenced by many factors that don't directly affect AbbVie's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AbbVie's value and its price as these two are different measures arrived at by different means. Investors typically determine if AbbVie is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AbbVie's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.